PAR 1.96% 25.0¢ paradigm biopharmaceuticals limited..

Where is the green?, page-135

  1. 60 Posts.
    lightbulb Created with Sketch. 10
    The fundamentals of the company haven't changed.
    The cash position is strong (fully funded)
    The drug clearly works, mountains of evidence, with a strong safety history.
    Competent experienced management.
    Massive future potential revenues with both application (OA, MPS).
    The last few months is just the market doing its thing, no need for an exit plan IMO.



 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.